Anesthetic considerations for Ehlers-Danlos syndrome

A perioperative guide for anesthesia providers — and for patients preparing to talk to their anesthesia team.

Reviewed and updated August 2026 · Written by Anastasia Jackson, DNAP, CRNA

What Ehlers-Danlos syndrome is, and why the subtype matters more than the label

The Ehlers-Danlos syndromes are a group of heritable connective tissue disorders affecting collagen synthesis, processing, or structure. The 2017 international classification recognizes 13 distinct subtypes, each with defined clinical criteria and, for all but one, an identified genetic basis.¹

This matters clinically because “the patient has EDS” is not enough information to plan an anesthetic. A patient with hypermobile EDS presenting for knee arthroscopy and a patient with vascular EDS presenting for the same operation face almost entirely different risks. The first is a positioning and analgesia problem. The second is a potential arterial catastrophe.

Preoperative assessment

Establish the subtype and the genetics

Ask directly whether genetic testing was performed and what it showed. A confirmed COL3A1 variant changes everything downstream. A clinical diagnosis of hypermobile EDS — which currently has no genetic test — does not carry the same vascular implications.

Obtain previous anesthetic records

This is the highest-yield item in the entire assessment and the most frequently skipped. Prior charts answer questions the physical exam cannot: was the airway difficult, did the block work, was there unexpected bleeding, did the patient have prolonged PACU stays or difficult emergence. Retrospective review of previous anesthesia records has been specifically recommended for this population precisely because the published evidence base is thin enough that individual history outweighs general guidance.³

Cardiac evaluation

Mitral valve prolapse and aortic root dilation occur across several subtypes. Echocardiography is reasonable in any patient with a murmur, a family history of aortic disease, or a subtype with known cardiovascular involvement. Cardiac-valvular EDS carries progressive, severe valve disease and warrants formal cardiology input.

Airway history

Ask about temporomandibular joint problems specifically — TMJ subluxation and dislocation are common, and a patient who dislocates their jaw yawning may dislocate it under laryngoscopy. Ask about neck pain, prior cervical imaging, and any diagnosis of craniocervical instability or Chiari malformation, both of which are over-represented in this population.

Bleeding history

Standard coagulation testing is frequently normal in patients who nonetheless bleed. Take a structured bleeding history rather than relying on labs — the ISTH bleeding assessment tool has been applied in EDS cohorts for exactly this reason, and work at the Toronto GoodHope EDS Clinic has examined point-of-care testing including rotational thromboelastometry and functional platelet assays against bleeding severity scores.⁴

Dysautonomia and POTS

Postural orthostatic tachycardia syndrome co-occurs frequently with hypermobile EDS and materially affects the anesthetic. Reported management centers on adequate preoperative hydration, careful positioning during induction, and anticipating hemodynamic lability on emergence.⁵ Ask about baseline blood pressure, salt and fluid loading regimens, midodrine or fludrocortisone use, and how long the patient has been NPO — prolonged fasting is poorly tolerated.

Mast cell activation syndrome

MCAS is commonly reported alongside hypermobile EDS. Where it is present, histamine-releasing agents warrant caution, and continuing the patient’s antihistamine regimen through the perioperative period is reasonable.⁶

Gastrointestinal function

Gastroparesis and functional GI symptoms are common in hypermobile EDS. Consider aspiration risk, and consider gastric ultrasound if the history suggests delayed emptying.

Medication review

Patients with vascular EDS may be taking celiprolol or an angiotensin receptor blocker specifically to reduce arterial event risk. These should generally be continued. Chronic opioid, NSAID, and anticoagulant use are all common and all relevant.

Airway management

The airway concerns in EDS are mechanical, not anatomical in the conventional difficult-airway sense. Most patients intubate normally. The risk is what the intubation does to them.

Temporomandibular joint

TMJ subluxation is a recognized risk during laryngoscopy and mask ventilation. Minimize mouth opening force, avoid aggressive jaw thrust, and consider that a patient with recurrent TMJ dislocation may benefit from a technique requiring less mouth opening.

Cervical spine

Cervical instability has been described in EDS and is a specific concern in vascular EDS.⁷ Published case management emphasizes avoiding neck hyperextension during intubation and maintaining vigilance for cervical subluxation through emergence and extubation.⁵ Videolaryngoscopy is a reasonable default because it reduces the cervical movement required. Awake fiberoptic intubation has been recommended where instability is documented or suspected.⁶

Mucosal and dental fragility

Airway mucosa tears more readily. Use gentle technique, adequate lubrication, a smaller tube than you might otherwise select, and avoid repeated attempts. Periodontal EDS carries early tooth loss, and dental fragility is worth documenting before instrumentation.

Supraglottic airways

An LMA has been used successfully and may be preferable where it avoids laryngoscopy altogether.⁸ Balance that against aspiration risk if gastroparesis is present.

Ventilation and pneumothorax

Spontaneous pneumothorax is described in several subtypes. In a reported case of musculocontractural EDS undergoing scoliosis surgery, pressure-controlled ventilation with limited peak inspiratory pressure was used specifically to prevent pneumothorax.² Lung-protective ventilation with attention to peak pressures is a reasonable default.

Local anesthetic resistance — what the evidence actually shows

This is the single most distinctive anesthetic feature of EDS, the one patients most often report being disbelieved about, and the area where the evidence has changed most recently.

The evidence, in order

1990 — the original observation. A Danish group taking skin biopsies noticed that patients with EDS type III experienced significant pain despite conventional local anesthesia. In the resulting controlled study of 8 patients and 8 controls, both groups achieved analgesia five minutes after intradermal lidocaine, but by 60 minutes the effect had disappeared in the EDS group while persisting in controls. Topical EMLA cream failed to produce adequate analgesia in the EDS patients while controls achieved full anesthesia.⁹

2005 — the clinical signal. Hakim and colleagues reported that a majority of joint hypermobility syndrome patients surveyed described partial or complete local anesthetic failure, and noted that some had previously been dismissed as exaggerating.¹⁰

2019 — the large survey. Among 980 EDS respondents who had received local anesthesia for a dental procedure, 88% recalled inadequate pain prevention, compared with 33% of 249 non-EDS respondents. By agent, the reported success rates were articaine 30%, bupivacaine 25%, and mepivacaine 22% — with lidocaine and procaine reported effective far less often.¹¹ Note what this means: even the best-performing agent worked in fewer than a third of patients.

2022 — resistance across multiple routes. A case report described a laboring patient in whom two technically uneventful epidurals provided no analgesia, the spinal component of a subsequent combined spinal-epidural was also ineffective, and an attempted pudendal block with lidocaine had no effect. General anesthesia was ultimately required for cesarean delivery. The authors described it as the first report of local anesthetic resistance by three distinct routes in one patient.¹²

2026 — the randomized trial. The strongest evidence to date. In a randomized cross-over design, 135 participants (91 with EDS, 44 healthy controls) received subcutaneous saline and lidocaine at separate forearm sites, with sensation assessed by standardized monofilament. At five minutes there was no difference between groups. At 15 and 30 minutes, adequate anesthesia was present in 60% versus 84% (p = 0.006) and 53% versus 80% (p = 0.003) respectively.¹³

What to do about it

• Believe the history. A patient who tells you lidocaine does not work for them is describing a phenomenon with controlled evidence behind it.
• Ask which agents have worked before. Response appears agent-specific, and the survey data favor articaine, bupivacaine, and mepivacaine over lidocaine and procaine.¹¹
• Prefer longer-acting agents where the procedure allows, since the failure mode is duration rather than onset.
• Re-test the block before incision, and again later — not only at five minutes.
• Have a plan B stated out loud before starting, especially for awake procedures and labor analgesia. The patient should know what happens if the block fails.
• Do not exceed maximum safe doses chasing an inadequate block. Resistance is not a reason to escalate past toxic thresholds; it is a reason to change technique. Ceilings for every agent are tabulated at local anesthetic maximum doses.

Regional and neuraxial anesthesia

Neuraxial techniques are not contraindicated in EDS and have been used successfully, including in obstetrics.³ Several considerations modify the risk-benefit calculation.

Bleeding and hematoma

Increased epidural hematoma risk has been raised specifically in the context of vascular-type EDS, alongside the general concern for excessive bleeding.⁷ In subtypes with vascular fragility, weigh this carefully. In hypermobile EDS without a bleeding phenotype, the concern is smaller but not zero.

Technical difficulty and dural puncture

Connective tissue laxity may make landmarks less reliable and the epidural space harder to identify. Ultrasound guidance has been used and is reasonable — a recent case report of cesarean delivery in classical EDS described ultrasound-guided spinal anesthesia as part of a coordinated multidisciplinary plan.¹⁵ Post-dural puncture headache risk is described as elevated in this population.⁶

Peripheral nerve blocks

Reasonable and often desirable given the opioid-sparing benefit in a population with high chronic pain prevalence. Apply the same local anesthetic resistance caveats: verify the block, expect shorter duration than usual, and consider a catheter rather than a single shot where the procedure warrants it.

General anesthesia

Agent selection

There are no subtype-specific agent contraindications. Where MCAS is present, caution with histamine-releasing agents is advised, and induction agents producing minimal hemodynamic change have been suggested as preferable in patients with dysautonomia.⁶

Neuromuscular blockade

Succinylcholine is not contraindicated by EDS itself. The standard exception applies: avoid depolarizing agents in patients who are immobilized, where upregulation of extrajunctional receptors creates hyperkalemia risk independent of the connective tissue diagnosis. Because some subtypes involve muscle weakness — myopathic EDS most obviously — quantitative neuromuscular monitoring before emergence is specifically advised.³

Opioid response

Unpredictable opioid response is widely reported in this population, though the evidence is largely anecdotal.⁶ Many patients have substantial chronic opioid exposure and correspondingly elevated requirements. Multimodal, opioid-sparing strategies have been described specifically for hypermobile EDS.

Positioning, skin, and the injuries that actually happen

If a patient with EDS is harmed perioperatively, this is the most likely mechanism. The injuries are preventable and they are mechanical.

Joint subluxation and dislocation

Joints that dislocate during ordinary activity will dislocate under anesthesia, when protective muscle tone is gone and the patient cannot report discomfort. Position the patient before induction where possible and ask them to confirm the position is comfortable and sustainable. Avoid extremes of abduction, rotation, and traction. Move the patient as a unit, with enough hands.

Peripheral nerve injury

A case of perioperative brachial plexus injury caused by upper extremity hyperabduction in the prone position has been reported specifically in a patient with EDS.¹⁶ Standard positioning limits should be treated as maximums rather than targets.

Skin and adhesive injury

Skin tears from shear force and from medical adhesives are a genuine risk, particularly in classical and dermatosparaxis subtypes. Reported mitigation includes low-rebound mattresses to reduce shear and external pressure, and barrier films to prevent medical adhesive–related skin injury.² Practically: use paper tape or silicone-based dressings, avoid aggressive adhesive removal, consider a barrier film under any adhesive, and pad generously.

Tourniquets

Tourniquet use warrants explicit discussion with the surgeon in subtypes with vascular fragility, given the risk of hematoma, compartment syndrome, and diffuse bleeding.³

Eyes

Brittle cornea syndrome and scleral fragility in kyphoscoliotic EDS make eye protection non-optional. Avoid any pressure on the globe.

Bleeding and hemostasis

Easy bruising and prolonged bleeding are common across subtypes and frequently occur with entirely normal routine coagulation studies. The defect is in the vessel wall and perivascular connective tissue rather than in the coagulation cascade.

• Do not be reassured by a normal PT/INR and platelet count. Take the history.
• Desmopressin has been studied for EDS-associated bleeding symptoms and is a reasonable consideration in patients with a documented phenotype.¹⁷
• Tranexamic acid is a reasonable adjunct in procedures with meaningful expected blood loss.
• Viscoelastic testing (TEG or ROTEM) has been used to guide hemostatic management, including in a reported case of severe perioperative bleeding during scoliosis surgery in musculocontractural EDS.²
• Vascular access is itself a bleeding risk. Expect hematoma from IV attempts, use ultrasound, and minimize attempts.

Vascular EDS: a different problem entirely

Vascular EDS results from pathogenic variants in COL3A1, which encodes type III procollagen — a major structural protein of vessel walls and hollow organs. Estimated frequency is between 1 in 50,000 and 1 in 200,000.¹⁸ Characteristic features include thin translucent skin, easy bruising, distinctive facial features, arterial dissection and rupture, and spontaneous rupture of bowel or the gravid uterus. Roughly a quarter of patients experience a vascular complication before age 20, rising to about 80% by age 40.¹⁹

Anesthetic implications

• Vascular access is both difficult and hazardous. Arterial puncture carries real risk. Where invasive monitoring is genuinely required, weigh it explicitly rather than placing lines by default, and use ultrasound.
• Spontaneous arterial rupture can occur perioperatively — a documented concern independent of surgical manipulation.⁷
• Blood pressure control is the central medical intervention. Avoid hypertensive surges at laryngoscopy, emergence, and extubation. Treat coughing and straining as hemodynamic events.
• Cervical instability and airway trauma risk are specifically described in this subtype.⁷
• Bowel and uterine rupture may be the presenting surgical problem, which means these patients can arrive as emergencies without a known diagnosis.

Celiprolol and medical therapy

The BBEST trial — a prospective randomized open, blinded-endpoint study — reported a substantially reduced hazard of arterial events with celiprolol, a beta-1 antagonist with beta-2 agonist vasodilatory activity, titrated up to 400 mg daily.²⁰ The result has been questioned because a proportion of participants lacked genetically confirmed COL3A1 variants, and subsequent cohort studies have reported both tolerability limits and continued fatal events on treatment.²¹ A randomized trial of irbesartan has since been published, and current practice emphasizes strict blood pressure control with beta-blockers and angiotensin receptor blockers, alongside surveillance imaging and lifestyle modification.^19,22

For the anesthesia provider the practical point is narrower: these medications should generally be continued perioperatively, and their presence in the medication list is itself a signal that the patient has confirmed vascular EDS.

Surgery in vascular EDS

Historically, surgical intervention was avoided until complications developed, on the reasoning that tissue fragility made operating hazardous. That position has been modified in selected cases, and endovascular approaches previously avoided in connective tissue disorders have been reported as feasible.^23,24 This is a decision for a multidisciplinary team at a center with experience, not a decision to be made intraoperatively.

Obstetric considerations

Pregnancy in EDS carries elevated risk of prematurity, hemorrhage, and maternal morbidity. In vascular EDS specifically, uterine rupture and arterial rupture during pregnancy and delivery are recognized causes of maternal death, and early planned cesarean delivery has been advocated to avoid severe lacerations.²⁵

A recent case report of elective cesarean delivery in classical EDS describes the shape of good practice: a multidisciplinary plan built in advance with cardiology, hematology, endocrinology and pulmonology input, ultrasound-guided spinal anesthesia, and extended post-anesthesia observation.¹⁵ The recurring theme across the obstetric literature is that the plan should exist weeks before labor, not on arrival.

Labor analgesia deserves particular attention given the local anesthetic resistance data — the multi-route failure case described above occurred in a laboring patient, and the fallback was general anesthesia for cesarean delivery.¹²

Postoperative care

• Pain control is frequently inadequate in this population, reflecting both local anesthetic resistance and chronic pain with opioid tolerance. Plan multimodal analgesia deliberately rather than reactively.
• Watch for occult bleeding. A high index of suspicion is warranted given the combination of vessel fragility and normal-appearing coagulation studies.⁶
• Hemodynamic instability may persist where POTS or dysautonomia is present. Extended monitored observation is reasonable.¹⁵
• Wound healing is delayed. Sutures and adhesive strips are typically left in place substantially longer than usual, and multilayered tension-reducing closure is recommended.
• Post-dural puncture headache risk is elevated after neuraxial technique.⁶
• Joint protection continues into recovery — transfers from the operating table to the bed and from bed to chair are dislocation opportunities.

A practical preoperative checklist

Frequently asked questions

Is anesthesia safe for someone with Ehlers-Danlos syndrome?

Yes, with planning. Safe anesthesia can be provided with adequate preparation and appropriate resources.³ The risks are largely predictable and preventable: joint injury from positioning, skin damage from adhesives, airway trauma, bleeding, and inadequate local anesthesia. Vascular EDS carries additional and more serious risks that require specialist management.

Does local anesthetic really not work in EDS, or is that a myth?

It is real and it now has controlled evidence. A 2026 randomized cross-over trial found significantly reduced lidocaine effectiveness at 15 and 30 minutes in EDS patients compared with healthy controls, though not at 5 minutes.¹³ Earlier work showed the same pattern — normal onset, shortened duration.⁹ Survey data found 88% of EDS respondents reported inadequate pain prevention during dental procedures versus 33% of non-EDS respondents.¹¹

Which local anesthetic works best in Ehlers-Danlos syndrome?

Survey data suggest articaine performs best, followed by bupivacaine and mepivacaine, with lidocaine and procaine reported effective far less often. However, even the best-performing agent was reported effective in only about 30% of EDS respondents.¹¹ The most useful guide is the individual patient’s own history of what has worked.

Can people with EDS have an epidural or spinal?

Yes — neuraxial anesthesia is not contraindicated and has been used successfully, including for cesarean delivery.^3,15 The considerations are increased bleeding and hematoma risk in vascular subtypes, potentially difficult landmarks, elevated post-dural puncture headache risk, and the possibility that the block will be less effective or shorter-lived than expected.^6,12

Is Ehlers-Danlos syndrome linked to malignant hyperthermia?

No. EDS is not associated with malignant hyperthermia, and there is no evidence that EDS itself alters anesthetic pharmacokinetics or pharmacodynamics.³ This is one of the most common misconceptions about the condition.

What should I tell my anesthesia provider before surgery if I have EDS?

Your subtype and whether it was genetically confirmed; which local anesthetics have and have not worked for you; any history of joint dislocation and which joints; whether your skin tears with tape; whether you have POTS, MCAS, or gastroparesis; your bleeding history including dental extractions and childbirth; any neck or jaw problems; and — most usefully — records from any previous anesthetic.

Is surgery riskier with vascular EDS?

Yes, substantially. Vascular EDS carries risk of arterial dissection and rupture and spontaneous bowel or uterine rupture, with roughly 25% of patients experiencing a vascular complication before age 20 and about 80% by age 40.¹⁹ Elective surgery decisions should involve a multidisciplinary team with experience in the condition.

References

1. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. doi:10.1002/ajmg.c.31552
2. Wakabayashi R, Tanaka S, Tsuchiyama K, et al. Anesthetic management of a patient with musculocontractural Ehlers-Danlos syndrome undergoing scoliosis surgery. JA Clin Rep. 2020;6:41. doi:10.1186/s40981-020-00352-5
3. Wiesmann T, Castori M, Malfait F, Wulf H. Recommendations for anesthesia and perioperative management in patients with Ehlers-Danlos syndrome(s). Orphanet J Rare Dis. 2014;9:109. doi:10.1186/s13023-014-0109-5
4. Toronto General Hospital GoodHope EDS Clinic. Point-of-care testing (ROTEM, PlateletWorks) and ISTH-BAT bleeding severity scores in an adult EDS cohort, 2022–2024.
5. Laserna A, Nishtar M, Vidovich C, Borovcanin Z. Perioperative management of Ehlers-Danlos type III syndrome associated with postural orthostatic tachycardia in patients undergoing general anesthesia. Cureus. 2021;13(11):e19311. doi:10.7759/cureus.19311
6. Perioperative care in patients with Ehlers-Danlos syndromes. Review of coexisting conditions including dysautonomia, MCAS, Chiari malformation, craniocervical instability, gastroparesis, and altered local anesthetic response. Surgical Science. 2019.
7. Anaesthetic implications of vascular type Ehlers-Danlos syndrome. Anaesth Intensive Care. 2006. PMID 16913351
8. Perioperative anesthesia management in a patient with Ehlers-Danlos syndrome: a case report of scleral buckling surgery. Arch Anesth Crit Care. 2026.
9. Arendt-Nielsen L, Kaalund S, Bjerring P, Høgsaa B. Insufficient effect of local analgesics in Ehlers Danlos type III patients (connective tissue disorder). Acta Anaesthesiol Scand. 1990;34(5):358–361.
10. Hakim AJ, Grahame R, Norris P, Hopper C. Local anaesthetic failure in joint hypermobility syndrome. J R Soc Med. 2005;98(2):84–85.
11. Schubart JR, Schaefer E, Janicki P, et al. Resistance to local anesthesia in people with the Ehlers-Danlos syndromes presenting for dental surgery. J Dent Anesth Pain Med. 2019;19(5):261–270. PMID 31723666
12. Jacobs A, et al. Resistance to local anaesthetics administered via epidural, intrathecal and pudendal injections. Anaesth Rep. 2022;10(2):e12205. doi:10.1002/anr3.12205
13. Bourne KM, Thai S, Lei LY, et al. Patients with Ehlers-Danlos syndrome experience reduced effectiveness of lidocaine local anesthetic: a randomized cross-over clinical trial. Reg Anesth Pain Med. 2026. doi:10.1136/rapm-2025-107416. PMID 41775498. Note: this paper reports 44% versus 91% at 30 minutes in its abstract and 53% versus 80% in its results text, both at p = 0.003. The results-text figures are the ones quoted above.
14. Cesare AE, Rafer LC, Myler CS, Brennan KB. Anesthetic management for Ehlers-Danlos syndrome, hypermobility type complicated by local anesthetic allergy: a case report. Am J Case Rep. 2019;20:39–42. doi:10.12659/AJCR.912799
15. Aljuba YM, Shatalin D, Ronenson A, Grenader A, Ioscovich A. Anesthetic management of a pregnant patient with Ehlers-Danlos syndrome undergoing elective cesarean delivery: a case report. Cureus. 2025;17(8):e89400. doi:10.7759/cureus.89400
16. Ohashi N, Furutani K, Ishii H, Baba H. Perioperative brachial plexus injury caused by hyperabduction of the upper extremity in a patient with Ehlers-Danlos syndrome in the prone position. Masui. 2012;61(6):626–628.
17. Mast KJ, Nunes ME, Ruymann FB, Kerlin BA. Desmopressin responsiveness in children with Ehlers-Danlos syndrome associated bleeding symptoms. Br J Haematol. 2009.
18. Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):40–47. doi:10.1002/ajmg.c.31553
19. Varied presentations of arterial events in vascular Ehlers-Danlos syndrome. JACC Case Rep. 2025. doi:10.1016/j.jaccas.2025.105424
20. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial (BBEST). Lancet. 2010;376(9751):1476–1484.
21. Baderkhan H, Wanhainen A, Stenborg A, et al. Celiprolol treatment in patients with vascular Ehlers-Danlos syndrome. Eur J Vasc Endovasc Surg. 2021;61(2):326–331.
22. What every vascular surgeon should know about vascular Ehlers-Danlos syndrome. Ann Vasc Surg. 2026. doi:10.1016/j.avsg.2026.00196-2
23. Khoury MK, Eagleton MJ. Iliac artery aneurysm endoleak management in a patient with vascular Ehlers-Danlos syndrome. J Vasc Surg Cases Innov Tech. 2024. doi:10.1016/j.jvscit.2023.101401
24. Vascular complications of Ehlers-Danlos syndrome: CT findings. AJR Am J Roentgenol. doi:10.2214/AJR.11.6603
25. Diagnosis and management of vascular Ehlers-Danlos syndrome: experience of the UK national diagnostic service, Sheffield. Eur J Hum Genet. 2023. doi:10.1038/s41431-023-01343-7

← More clinical answers